Nature Reviews Urology - Table of Contents alert Volume 12 Issue 3

TABLE OF CONTENTS
March 2015 Volume 12 Number 3
Impact Factor4.522*	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Are androgen receptor variants a substitute for the full-length receptor?  Ji Lu, Travis Van der Steen & Donald J. Tindall
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Reach the widest possible audience in the shortest possible time Scientific Reports is the home for rapidly published, highly visible open access research. Multi-disciplinary in scope, we're open to all, publishing sound original research papers across the sciences without barriers to access. What can we do for your research?
RESEARCH HIGHLIGHTS Prostate cancer: MRI/TRUS fusion outperforms standard and combined biopsy approaches Published online: 17 February 2015 p119 | doi:10.1038/nrurol.2015.28 PDF Prostate cancer: Abiraterone treatment improves overall survival in patients with mCRPC Published online: 03 February 2015 p120 | doi:10.1038/nrurol.2015.14 PDF Testicular cancer: Tumour mutations identified Published online: 10 February 2015 p120 | doi:10.1038/nrurol.2015.22 PDF Bladder cancer: uPAR expression indicates worse prognosis of urothelial carcinoma Published online: 03 February 2015 p120 | doi:10.1038/nrurol.2015.5 PDF Prostate cancer: BAT-ting CRPC Published online: 27 January 2015 p121 | doi:10.1038/nrurol.2015.6 PDF Kidney cancer: Molecular subtype predicts sunitinib response in m-ccRCC Published online: 27 January 2015 p122 | doi:10.1038/nrurol.2015.7 PDF Kidney cancer: S1P—a promising target in sunitinib-resistant RCC Published online: 03 February 2015 p123 | doi:10.1038/nrurol.2015.16 PDF Incontinence: Stress less—balloon therapy is effective for SUI Published online: 03 February 2015 p123 | doi:10.1038/nrurol.2015.17 PDF Prostate cancer: No need to rush for men with low-risk disease Published online: 10 February 2015 p124 | doi:10.1038/nrurol.2015.23 PDF Prostate cancer: Breaking AKR1C3-mediated enzalutamide resistance by inhibiting androgen synthesis Published online: 24 February 2015 p124 | doi:10.1038/nrurol.2015.31 PDF Prostate cancer: AR targeting—it all makes sense Published online: 17 February 2015 p125 | doi:10.1038/nrurol.2015.26 PDF Surgery: Amniotic membrane nerve wrap improves continence and potency outcomes after robotic prostatectomy Published online: 03 February 2015 p126 | doi:10.1038/nrurol.2015.15 PDF Prostate cancer: Hypofractionation not associated with reduced toxicity Published online: 17 February 2015 p126 | doi:10.1038/nrurol.2015.27 PDF IN BRIEF Stones: Ureteroscopy without radiation exposure is feasible | Prostatitis:Acupuncture treatment for chronic prostatitis | Infectious disease: qHPV vaccine is not linked with multiple sclerosis| Prostate cancer: Metformin not associated with prostate cancer diagnosis | Prostate cancer: Predictors of high-grade tumours at radical prostatectomy | Prostate cancer:DTCs are not associated with clinical outcome | BPH: Are STIs linked with BPH/LUTS outcomes? | Prostate cancer:Reducing hospital admissions following prostate biopsyPDF
NEWS AND VIEWS
Prostate cancer: How good are guidelines for localized prostate cancer? John GrahamPublished online: 03 February 2015 p127 | doi:10.1038/nrurol.2015.3Numerous clinical practice guidelines on the treatment of localized prostate cancer exist, but methodological quality varies considerably. A new report evaluates published guidelines, assessing the rigour and applicability of the recommendations and suggesting areas that require improvement. Full Text | PDF
Kidney cancer: Systemic therapy—differentiating the achievable from the achieved Reza Mehrazin & Matthew D. GalskyPublished online: 20 January 2015 p128 | doi:10.1038/nrurol.2014.358Over the past few years the management of patients with metastatic renal cell carcinoma has changed substantially. Although the development of targeted therapies has improved the prognosis of many patients with renal cell carcinoma, a large subset of patients who might benefit from targeted therapies do not receive such treatments. Full Text | PDF
Prostate cancer: Predicting prostate biopsy results—PCA3 versus phi Stacy LoebPublished online: 03 February 2015 p130 | doi:10.1038/nrurol.2015.1Data comparing tests designed to predict the likelihood of finding significant prostate cancer on biopsy are limited. A comparison of two such tests—the Prostate Health Index (phi) and prostate cancer antigen 3 (PCA3) score—has found that phi outperforms PCA3 for predicting clinically significant prostate cancer. Full Text | PDF
Prostate cancer: Nerve-sparing surgery and risk of positive surgical margins Katharina Boehm & Markus GraefenPublished online: 06 January 2015 p131 | doi:10.1038/nrurol.2014.359A negative surgical margin in organ-confined prostate cancer is considered to be one criterion indicating a high-quality radical prostatectomy. Possible risk factors for positive surgical margins—including prostate volume, obesity or nerve-sparing surgery—have been investigated, but results are inconclusive. Cumulative evidence, however, indicates that surgical margin status is strongly influenced by surgical experience. Full Text | PDF
Prostate cancer: Bicalutamide dose increase in castration-resistant disease Fernand LabriePublished online: 09 December 2014 p132 | doi:10.1038/nrurol.2014.334The antiandrogen bicalutamide is commonly used in combination with medical or surgical castration in men with prostate cancer. With combined androgen blockade, the usual dose of bicalutamide is 50 mg per day, but evidence suggests that higher doses might be beneficial. Full Text | PDF
Prostate cancer: Identifying sites of recurrence with choline-PET-CT imaging Paolo Castellucci & Stefano FantiPublished online: 02 December 2014 p134 | doi:10.1038/nrurol.2014.321Management of biochemically recurrent prostate cancer can be determined by the use of nomograms based on risk factors, but this approach might not lead to selection of optimal courses of treatment for individual patients. Choline-PET-CT imaging can identify the sites of recurrence in these patients, enabling personalized treatment choices depending on the presence of localized or metastatic disease. Full Text | PDF
REVIEWS
Are androgen receptor variants a substitute for the full-length receptor? Ji Lu, Travis Van der Steen & Donald J. TindallPublished online: 10 February 2015 p137 | doi:10.1038/nrurol.2015.13Androgen receptor splice variants (AR-Vs) are expressed in castration-resistant prostate cancer (CRPC) and are constitutively active. AR-Vs are induced by several mechanisms, including androgen deprivation therapy, and could represent a novel therapeutic target for prostate cancer—especially in CRPC. This Review discusses the role of AR-Vs in prostate cancer progression and treatment resistance. Abstract | Full Text | PDF
Radiotherapy for high-risk prostate cancer Jahan J. Mohiuddin, Brock R. Baker & Ronald C. ChenPublished online: 24 February 2015 p145 | doi:10.1038/nrurol.2015.25Combining radiotherapy with long-term androgen deprivation therapy can provide an overall survival benefit in men with high-risk prostate cancer compared with either treatment alone. In this Review, Mohiuddin and colleagues describe relevant clinical studies and discuss novel radiation technologies and treatment combinations that could further improve cancer control and survival outcomes in this patient group. Abstract | Full Text | PDF
Risk-adapted strategy for the kidney-sparing management of upper tract tumours Thomas Seisen, Pierre Colin & Morgan RouprêtPublished online: 24 February 2015 p155 | doi:10.1038/nrurol.2015.24Radical nephroureterectomy has traditionally been the standard-of-care treatment for most patients with upper tract urothelial carcinomas (UTUCs). However, patients with normal kidney function might benefit from treatment with a kidney-sparing approach. Here, Morgan Roupret and colleagues describe the risk-adjusted, kidney-sparing treatment and management of patients with UTUCs and the associated risks and benefits, whilst also highlighting the indications for use of such an approach. Abstract | Full Text | PDF
PERSPECTIVES
OPINION Psychosocial perspectives on sexual recovery after prostate cancer treatment Lauren M. Walker, Richard J. Wassersug & John W. RobinsonPublished online: 10 March 2015 p167 | doi:10.1038/nrurol.2015.29Many patients experience impaired erectile function after prostate cancer treatment and struggle to resume a satisfying sexual relationship. In this Perspectives article, Walker, Robinson and Wassersug provide healthcare professionals with recommendations to facilitate successful sexual recovery and the best outcome for patients and their partners. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com  More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Urology was previously published as Nature Clinical Practice Urology.